{"entity":{"id":"tara-002","kind":"drug","name":"TARA-002","aka":[],"tldr":"TARA-002 is an experimental cell therapy whose type is not stated from Protara Therapeutics in phase 3 trials for bladder & urothelial cancer, with its target not yet stated publicly.","summary":"TARA-002 is a cell therapy whose type is not stated developed by Protara Therapeutics. The sponsor describes its target as non-muscle invasive bladder cancer and lymphatic malformations, which OnCo does not yet have a target page for. The sponsor states: TARA-002 is based on OK-432, a broad immunopotentiator that is approved in Japan and Taiwan for other indications. ClinicalTrials.gov describes the intervention as: All participants will receive 6 weekly instillations of TARA-002 at the established RP2D (First Treatment Period). Participants who are eligible for reinduction after the First Treatment Period will receive 6 additional weekly doses of TARA. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07480356 (Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer), in bladder & urothelial cancer. The largest, NCT07480356, plans to enrol 284 participants with primary completion expected 2028-04. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of TARA-002","url":"https://clinicaltrials.gov/search?intr=TARA-002"},{"label":"Sponsor page","url":"https://www.protaratx.com/"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["protara-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07480356","nct05951179"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"cell therapy (type not stated)","mechanism":"TARA-002 is based on OK-432, a broad immunopotentiator that is approved in Japan and Taiwan for other indications.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/tara-002/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"company":[{"id":"protara-therapeutics","kind":"company","name":"Protara Therapeutics","route":"/companies/protara-therapeutics/"}],"trial":[{"id":"nct07480356","kind":"trial","name":"Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer","route":"/trials/nct07480356/"},{"id":"nct05951179","kind":"trial","name":"Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer","route":"/trials/nct05951179/"}]}}